Pirfenidone use in patients with idiopathic pulmonary fibrosis may be linked to a lower incidence of lung cancer. Learn more.

Dublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Pirfenidone (CAS 53179-13-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ...

Dublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Pirfenidone (CAS 53179-13-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ...

The grant will fuel Dudeja's pivotal clinical trial, titled "Clinical Trial Evaluating Pirfenidone as a Novel Treatment for Chronic Pancreatitis." Pirfenidone, currently used to treat idiopathic lung ...

Receiving admilparant, an oral lysophosphatidic acid receptor 1 antagonist, for 26 weeks lowered percent-predicted FVC ...

Progressive pulmonary fibrosis is not a diagnosis so much as a disease behavior and a clinical phenotype, says Anna-Maria ...

The new chief medical officer of the Pulmonary Fibrosis Foundation speaks about patients in rural areas, research ...

ERS Summit emphasizes on advancing respiratory health in India: Shardul Nautiyal, Mumbai Friday, February 28, 2025, 08:00 Hrs [IST] The European Respiratory Summit in Mumbai marke ...

The UK IPF Registry has provided new insights into the evolving landscape of idiopathic pulmonary fibrosis management.

The product has been replaced with a new NDC number. Pirfenidone: Genetech has discontinued the 267-milligram presentation of pirfenidone capsule used for pulmonary/allergy treatments ...